ZnO quantum dot vector/DNA composite-containing collagen-based composite cornea substitute, and preparation method and application thereof

A technology of substitutes and quantum dots, which is applied in the field of collagen-based composite corneal substitutes, can solve problems such as biological toxicity restricting applications, achieve easy processing, long-term storage and transportation, improve stability and mechanical strength, and promote corneal regeneration. Effect

Inactive Publication Date: 2010-11-24
TIANJIN UNIV
View PDF5 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, CdX (X=S, Se, Te) quantum dots are the most widely used and most maturely prepared, but their great biological toxicity seriously restricts their application in the field of gene therapy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • ZnO quantum dot vector/DNA composite-containing collagen-based composite cornea substitute, and preparation method and application thereof
  • ZnO quantum dot vector/DNA composite-containing collagen-based composite cornea substitute, and preparation method and application thereof
  • ZnO quantum dot vector/DNA composite-containing collagen-based composite cornea substitute, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The proportion of each component of the collagen corneal substitute is as follows:

[0033] Pig skin type Ⅰ collagen: MPDSAH (mass ratio) 1:0

[0034] Coll-NH 2 :EDC:NHS (molar ratio) 1:1:1

[0035] (1) Preparation of cross-linked collagen corneal substitute: Take 0.5g of 13.7% pigskin type Ⅰ collagen solution into a syringe, and connect another syringe to seal through a T-shaped container, push and pull repeatedly to mix well, and then use a micro-syringe to measure Inject crosslinkers EDC and NHS, where Coll-NH 2 : EDC: NHS = 1: 1: 1 (molar ratio), push and pull repeatedly to mix evenly, then add an appropriate amount of 2mol / L NaOH solution with a micro syringe to adjust the pH to about 5.5. After mixing evenly, the solution was poured into the mold, and then put into the clamp to fix it, 100% humidity, reacted at room temperature for 16 hours, and then moved into an oven at 37°C for aging for 5 hours. Remove the jig, open the mold and take out the corneal sample...

Embodiment 2

[0039] The proportions of the components of the collagen / MPDSAH composite corneal substitute are as follows:

[0040] Pig skin type Ⅰ collagen: MPDSAH (mass ratio) 1:0.3

[0041] Coll-NH 2 :EDC:NHS (molar ratio) 1:1:1

[0042] MPDSAH: PEGDA (mass ratio) 2:1

[0043] Irgacure2959: MPDSAH (molar ratio) 0.02:1

[0044] The steps of preparing the bioactive composite corneal substitute with the above-mentioned components are as follows:

[0045] (1) Preparation of composite corneal substitute: Take 0.5g of 13.7% pigskin type Ⅰ collagen solution into a syringe, and connect another syringe to seal through a T-shaped container, push and pull to mix evenly; the measured amount is pig skin type Ⅰ collagen : The MPDSAH of MPDSAH=1:0.3 (mass ratio) is dissolved in water, moves into the T-shaped container through the sealing pad with a micro-injector, pushes and pulls repeatedly to mix evenly, then injects cross-linking agent EDC, NHS and photoinitiator Irgacure 2959 sequentially with ...

Embodiment 3

[0049] The proportions of the components of the collagen / MPDSAH composite corneal substitute are as follows:

[0050] Pig skin type Ⅰ collagen: MPDSAH (mass ratio) 1:1

[0051] Coll-NH 2 :EDC:NHS (molar ratio) 1:1:1

[0052] MPDSAH: PEGDA (mass ratio) 2:1

[0053] Irgacure2959: MPDSAH (molar ratio) 0.02:1

[0054] The steps of preparing the bioactive composite corneal substitute with the above-mentioned components are as follows:

[0055] (1) Preparation of composite corneal substitute: Take 0.5g of 13.7% pigskin type Ⅰ collagen solution into a syringe, and connect another syringe to seal through a T-shaped container, push and pull to mix evenly; the measured amount is pig skin type Ⅰ collagen : The MPDSAH of MPDSAH=1:1 (mass ratio) is dissolved in water, moves into the T-shaped container through the sealing gasket with a micro-injector, pushes and pulls repeatedly to mix evenly, then injects cross-linking agent EDC, NHS and photoinitiator Irgacure 2959 sequentially with a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to a ZnO quantum dot vector / DNA composite-containing collagen-based composite cornea substitute, and a preparation method and application thereof. The ZnO quantum dot vector / DNA composite-containing collagen-based composite cornea substitute is prepared by absorbing ZnO quantum dot vectors / DNA composites by using a collagen / MPDSAH IPN cornea substitute, wherein the weight ratio of the cornea substitute to the ZnO quantum dot vectors / DNA composites is 425:1; and the weight ratio of ZnO quantum dot vectors to DNA is 25:1. The ZnO quantum dot vector / DNA composite-containing collagen-based composite cornea substitute has high biocompatibility, can induce and promote the regeneration of a cornea and be biologically decomposed along with the regeneration of the cornea, hasmechanical properties and optical properties the same as those of a human cornea, remarkably improves the stability and mechanical strength of the cornea substitute in collagenase due to the introduction of an MPDSAH polymer network, can effectively compositely compress the DNA, successfully induce the DNA into cells, successfully express the DNA, trace the position of the DNA / vector at any time and determine the intra-cellular distribution of the DNA / vector in a transgenosis process due to ZnO quantum dots, and effectively combines gene transfection, tissue engineering and fluorescent tracing so as to achieve simple manufacturing method, and easy processing and long-term storage and transport.

Description

technical field [0001] The invention relates to a collagen-based composite corneal substitute containing a ZnO quantum dot carrier / DNA complex and a preparation method and application thereof. It is a collagen-based composite corneal substitute loaded with a bioimaging function transgene carrier and a preparation method thereof, and uses tissue engineering and gene transfection to treat ophthalmology-related diseases. Background technique [0002] As a blinding eye disease with high incidence, corneal disease has been paid more and more attention by people. Since the endothelial cells of the cornea cannot be repaired or replaced automatically, allogeneic keratoplasty has become the most effective method of treating corneal diseases, but allogeneic keratoplasty has resulted in a great demand for donor corneas, and there is an unhealthy In addition, the incidence of postoperative immune rejection is still high. In view of this, it is urgent to develop an alternative to alloge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L27/26A61L27/24A61L27/16A61L27/54
CPCA61L2300/258A61K9/0051A61L2430/16A61L2300/624A61L2400/12A61L27/54A61K9/19A61K31/711A61K33/30A61K9/0012A61K33/08A61L27/24A61L27/52A61P27/02A61K2300/00
Inventor 刘文广刘贵培杨建海张鹏
Owner TIANJIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap